Award notice, first published as special notice
Illuccix PSMA VASD
36C26225Q0343
Department of Veterans Affairs, 262-Network Contract Office 22. Pharmaceutical Preparation Manufacturing.
Awarded
$538,575.00 obligated so far on USAspending
Get the next one like this from Department of Veterans Affairs by email, the day it is posted.Find my opportunities
This one was awarded in 2025
9 like it are open now in pharmaceutical preparation manufacturing
- FY27 Low Energy General Radiopharmaceuticals 36C25027Q0052
Department of Veterans Affairs, 250-Network Contract Office 10
Sources soughtNAICS 325412Anywhere in the US36C25027Q0052Closes in 2 daysNov 3 - Sacubitril/Valsartan Tablets (VA-27-00014055)
Department of Veterans Affairs, Nac Pharmaceuticals
PresolicitationNAICS 325412Anywhere in the US36E79727R0007Closes in 2 daysNov 3 - LIDOCAINE 5% PATCHES-REQUEST FOR INFORMATION
Department of Veterans Affairs, National Cmop Office
Sources soughtNAICS 325412Anywhere in the US36C77027Q0010Closes in 2 daysNov 3
Description
As published on SAM.gov with the special notice of January 13, 2025.
This notice is published IAW Federal Acquisition Regulation (FAR) Subpart 5.101 requiring posting of information for proposed contract actions.
The Department of Veterans Affairs (VA), Network Contracting Office (NCO) 22, located at 4811 Airport Plaza Drive, Long Beach, CA 90815 intends to award a sole source firm-fixed price contract to Cardinal Health 414, LLC under the authority of FAR 8.405-6(a)(1)(B), Only one source is capable of providing the supplies or services required at the level of quality required because the supplies or services are unique or highly specialized..
The North American Industry Classification System (NAICS) for this requirement is 325412, Pharmaceutical Preparation Manufacturing. The Federal Supply Class (FSC) is 6505, Drugs and Biologicals. The Small Business Administration (SBA) size standard for this sector is 1,300 Employees.
VA San Diego Healthcare System Nuclear Medicine Service has a requirement for Illuccix PSMA radioactive therapy injection used with a medical imaging procedure called Positron Emission Tomography (PET) of lesions identified as prostate-specific membrane antigen (PSMA) positive.
ILLUCCIX is FDA approved for used in patients with prostate cancer whose cancer may have spread to other parts of the body and may need initial therapy or whose cancer may have come back, based on elevated serum prostate-specific antigen (PSA) levels.
If your firm provides the radiopharmaceutical therapy on GSA Federal Supply Schedule or any Federal Supply Schedule, please provide applicable contract number and identify which supply/service are applicable to that FSS contract, and the following additional information (1) A tailored capability statement indicating the firm s ability to provide a product and related services; (2) The respondents SAM UEI number, organization name, address, point of contact, and size and type of business (e.g., SDVOSB/VOSB, etc,) pursuant to the applicable NAICS code; (3) Information should be provided electronically in a Microsoft Word or Adobe PDF format.
Potential offerors must be a manufacturer or fully licensed, authorized distributor for the radiopharmaceutical items. Potential offerors must be FDA certified and deliver the radiopharmaceutical IAW Nuclear Regulatory Commission (NRC) and FDA regulations. This notice of intent is not a request for competitive quotes. However, interested parties may identify their interest and capability to respond to the requirement and submit capability statement no later than 10:00 am., PT, Tuesday, January 21, 2025, to:
Hestia.Sim@va.gov. Responses received will be evaluated; however, a determination by the Government not to compete the proposed procurement based upon responses received to this notice is solely within the discretion of the Government. If no written response is received within the closing date of this notice, a single delivery order purchase award will be made to Cardinal Health 414, LLC without any further notice.
This notice does not obligate the Government to award an agreement or otherwise pay for the information provided in response to this notice. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization's qualifications to perform the work.
Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. However, responses to this notice will not be considered adequate responses to a notice.
The contract, on USAspending
Federal procurement data the awarding office reported to FPDS, matched to this solicitation by its number.
- Recipient
- Telix Pharmaceuticals US Inc.
- UEI
- NMRHMBK4YTH7
- CAGE
- 8CP27
- Vendor location
- Fishers, IN
- Contract
- 36C26225F0243 under 36F79722D0197, delivery order
- Obligated
- $538,575.00
- Actions
- 4 between January 28, 2025 and March 10, 2026
- Competition
- Full and Open Competition, 1 offer received
- Described as
- Illuccix Psma Vasd
- Match
- solicitation number 36C26225Q0343 equals the FPDS solicitation identifier; same awarding office 36C262 (high confidence)
- Record
- USAspending award page
Publications
Every notice SAM.gov issued under this solicitation number, oldest first. Each is a separate record on SAM.
Points of contact
- Hestia Sim, Contract SpecialistHestia.Sim@va.gov